Camurus receives highest level in My Green Lab certification

Camurus receives the highest level (Green) in certification from My Green Lab (MGL), a leading nonprofit organization promoting sustainability in scientific research. Laboratory practices were evaluated across key areas including energy efficiency, water conservation, waste management, resource use, procurement, and green chemistry. Certification levels range from Bronze to Green, with Green being the highest.

“This achievement reflects Camurus’ commitment to further integrate environmentally responsible and sound sustainability practices into our laboratory operations, without compromising scientific excellence”, says Markus Johnson, Senior Vice President R&D at Camurus. “The certification is a valuable and quantitative tool for enhancing our structured sustainability work within the laboratories and supports our strive for continuous improvement.”

Camurus initiated the certification process in November 2024 with a baseline assessment and improvement recommendations from MGL. Throughout 2025, the company systematically implemented targeted changes, supported by a formed Green Team and a dedicated My Green Lab Ambassador appointed to lead the efforts. The certification received in November 2025 is valid for two years.

“The ambition is for sustainability to be embedded throughout our entire value chain”, says Iris Rehnström, Director Sustainability at Camurus. “This includes our research and development activities and the employees working in our laboratories. The certification marks an important and natural step within our sustainability journey.”

Endorsed by the UN-backed Race to Zero and recommended by the U.S. Environmental Protection Agency (EPA), the MGL certification is considered the gold standard for sustainable laboratory practices. Learn more: https://mygreenlab.org/programs/mgl-certification/

For more information
Iris Rehnström, Director Sustainability
[email protected]

About Camurus
Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe and chronic diseases. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal^® technology and its extensive R&D expertise. The R&D pipeline includes products for the treatment of dependence, pain, cancer, and endocrine diseases. Camurus has operations across Europe, the US, and Australia, with headquarters in Lund, Sweden. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com and LinkedIn.